Research Articles | Page 8 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis Dec 2019 Leukemia Myelodysplastic Syndromes (MDS)
What causes aplastic anaemia? Apr 2023 Leukemia Aplastic Anemia
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria Jan 2021 Leukemia Paroxysmal Nocturnal Hemoglobinuria (PNH)
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) Jul 2020 Leukemia Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index Sep 2020 Leukemia Myelodysplastic Syndromes (MDS)
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study Oct 2023 Leukemia Aplastic Anemia
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Jan 2019 Leuk Lymphoma. Myelodysplastic Syndromes (MDS)
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT Oct 2023 Lancet Hematology Myelodysplastic Syndromes (MDS)
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)